Romo-TenaJGómez-MartínDAlcocer-VarelaJ. CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance. Autoimmun Rev2013;12:1171–6, doi:10.1016/j.autrev.2013.07.002.
2.
WeinbergABoulwareDDigheroB. Effect of abatacept on immunogenicity of vaccines in individuals with type 1 diabetes. Vaccine2013;31:4791–4, doi:10.1016/j.vaccine.2013.07.086.
3.
KeatingGM. Abatacept: a review of its use in the management of rheumatoid arthritis. Drugs2013;73:1095–119, doi:10.1007/s40265-013-0080-9.
4.
BaoJLiTZhaoJZhangC-Y. Cytotoxic T lymphocyte-associated antigen 4 Ig-induced asthma in the treatment of rheumatoid arthritis. J Rheumatol2012;39:1903, doi:10.3899/jrheum.120327.
5.
HanifinJMRajkaG. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh)1980;59:44–7.
6.
WeinblattMEGenoveseMCSchiffMH. Immunogenicity is low and transient with intravenous abatacept therapy: results from a large pooled analysis of 3985 patients with rheumatoid arthritis (RA) and up to 8 years' exposure. Presented at the 2011 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Scientific Meeting; 5–9 Nov 2011; Chicago (IL).
KonstaMRallisEKaramerisA. Psoriasiform lesions appearing in three patients with rheumatoid arthritis during therapeutic administration of abatacept, a selective inhibitor of T-cell costimulation. J Eur Acad Dermatol Venereol2012;26:257–8, doi:10.1111/j.1468-3083.2011.04042.x.
9.
PieperJHerrathJRaghavanS. CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients. BMC Immunol2013;5:14–34.
